Blue Trust Inc. Grows Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Blue Trust Inc. grew its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 232.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,987 shares of the company’s stock after buying an additional 4,883 shares during the period. Blue Trust Inc.’s holdings in Amylyx Pharmaceuticals were worth $26,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in AMLX. abrdn plc lifted its holdings in shares of Amylyx Pharmaceuticals by 1,567.9% in the 3rd quarter. abrdn plc now owns 1,972,242 shares of the company’s stock valued at $6,390,000 after acquiring an additional 1,853,995 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Amylyx Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock valued at $42,000 after purchasing an additional 5,104 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Amylyx Pharmaceuticals by 41.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 880,745 shares of the company’s stock valued at $2,854,000 after purchasing an additional 258,818 shares during the last quarter. FMR LLC boosted its holdings in shares of Amylyx Pharmaceuticals by 292.0% in the 3rd quarter. FMR LLC now owns 221,001 shares of the company’s stock worth $716,000 after purchasing an additional 164,622 shares during the period. Finally, Alpha Wave Global LP bought a new position in shares of Amylyx Pharmaceuticals during the 3rd quarter valued at approximately $2,169,000. 95.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMLX. Baird R W upgraded Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Amylyx Pharmaceuticals in a report on Thursday, December 5th. Robert W. Baird upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their price target for the company from $3.00 to $11.00 in a report on Monday, November 18th. Bank of America raised shares of Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $4.20 to $10.00 in a research report on Wednesday, October 23rd. Finally, Leerink Partners set a $4.00 target price on Amylyx Pharmaceuticals and gave the company a “market perform” rating in a research report on Friday, October 18th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Amylyx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

Insider Activity at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 7,471 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $4.04, for a total transaction of $30,182.84. Following the transaction, the chief executive officer now owns 3,176,788 shares of the company’s stock, valued at approximately $12,834,223.52. This trade represents a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Joshua B. Cohen sold 11,851 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $3.47, for a total transaction of $41,122.97. Following the completion of the sale, the chief executive officer now directly owns 3,201,247 shares of the company’s stock, valued at $11,108,327.09. The trade was a 0.37 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,000 shares of company stock worth $84,142. Company insiders own 11.70% of the company’s stock.

Amylyx Pharmaceuticals Price Performance

Amylyx Pharmaceuticals stock opened at $3.74 on Tuesday. The stock has a market cap of $256.38 million, a price-to-earnings ratio of -0.98 and a beta of -0.54. The firm has a 50-day moving average of $3.95 and a two-hundred day moving average of $3.69. Amylyx Pharmaceuticals, Inc. has a 1 year low of $1.58 and a 1 year high of $19.95.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.